Deleting the enzymes that break down endocannabinoids had wide-ranging effects on lipid signaling throughout the brain, extending far beyond just endocannabinoids to affect prostaglandins, arachidonic acid, and dozens of related lipids.
Read this if you follow endocannabinoid system research or are interested in how cannabis-related enzyme inhibitors affect broader brain chemistry.
MAGL deletion reduced inflammatory PGE2 throughout the brain alongside 2-AG increases
What the researchers found
The endocannabinoid system is often thought of in terms of two molecules (anandamide and 2-AG) and two receptors (CB1 and CB2). This study revealed it is far more interconnected with broader lipid signaling networks than previously appreciated.
Using mice with deleted FAAH, MAGL, or CB1 receptors, researchers measured over 70 lipids across eight brain regions. The findings were striking:
Deleting MAGL (which breaks down 2-AG) massively increased 2-AG levels while significantly reducing arachidonic acid and the inflammatory prostaglandin PGE2 throughout the brain. Deleting FAAH (which breaks down anandamide) increased anandamide but did not affect arachidonic acid or PGE2, suggesting FAAH-derived arachidonic acid does not contribute to steady-state inflammatory lipid levels.
Deleting CB1 receptors left anandamide and 2-AG unchanged but increased PGE2 in most brain areas, suggesting the receptor itself normally limits inflammatory signaling.
Why it matters
This study fundamentally expands our understanding of what the endocannabinoid system does. Rather than being an isolated signaling system, it is deeply embedded in broader lipid networks that control inflammation, neurotransmission, and cell function. This has major implications for predicting the effects of drugs that target endocannabinoid enzymes.
The numbers in context
Over 70 lipids measured per sample. 8 brain regions analyzed. MAGL deletion: 2-AG up, AA and PGE2 down throughout brain. FAAH deletion: AEA up, no change in AA or PGE2. CB1 deletion: AEA and 2-AG unchanged, PGE2 up in most regions.
How the study worked
Targeted lipidomics in FAAH knockout, MAGL knockout, and CB1 knockout mice compared to wild-type controls. Over 70 lipids measured per sample using HPLC/MS/MS across eight brain regions (brainstem, cerebellum, cortex, hippocampus, hypothalamus, midbrain, striatum, thalamus).
What this study cannot tell us
Knockout models represent complete gene deletion, which is more extreme than pharmacological inhibition. Steady-state lipid levels may not reflect dynamic changes during actual signaling. Mouse brain lipid metabolism may differ from humans. Regional variation was observed but not always explained.
How to read the evidence
Comprehensive lipidomics study with multiple knockout models and eight brain regions, but entirely in mice with uncertain clinical translation.
When this study was published
Published in 2016. Understanding of the endocannabinoid lipidome has continued to expand with improved analytical methods.
The bigger picture
Drugs that inhibit FAAH or MAGL are being developed for pain, anxiety, and other conditions. This study shows that these drugs will affect far more than just endocannabinoid levels, with potentially beneficial (anti-inflammatory for MAGL inhibitors) or unpredicted (off-target lipid changes) consequences.
Questions still open
- Do MAGL inhibitors' anti-inflammatory effects (via reduced PGE2) contribute to their therapeutic potential? Why does FAAH-derived arachidonic acid not contribute to steady-state prostaglandin levels? Could the off-target lipid effects explain unexpected side effects of endocannabinoid-modulating drugs?
Common questions
What happens when you block the enzymes that break down endocannabinoids?
Why does this matter for drug development?
Read the original research
Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.
Pharmacological research, 110, 159-172
Citation
Leishman, Emma; Cornett, Ben; Spork, Karl; Straiker, Alex; Mackie, Ken; Bradshaw, Heather B. (2016). Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.. Pharmacological research, 110, 159-172. https://doi.org/10.1016/j.phrs.2016.04.020
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)